Growth Metrics

bioAffinity Technologies (BIAF) Receivables - Net (2021 - 2026)

bioAffinity Technologies has reported Receivables - Net over the past 6 years, most recently at $685235.0 for Q1 2026.

  • Quarterly Receivables - Net fell 28.9% to $685235.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $685235.0 through Mar 2026, down 28.9% year-over-year, with the annual reading at $541962.0 for FY2025, 52.43% down from the prior year.
  • Receivables - Net was $685235.0 for Q1 2026 at bioAffinity Technologies, up from $541962.0 in the prior quarter.
  • Over five years, Receivables - Net peaked at $1.6 million in Q2 2024 and troughed at $9930.0 in Q3 2022.
  • The 5-year median for Receivables - Net is $685235.0 (2026), against an average of $685944.9.
  • Year-over-year, Receivables - Net skyrocketed 11062.28% in 2023 and then crashed 73.56% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $10489.0 in 2022, then soared by 7638.34% to $811674.0 in 2023, then surged by 40.35% to $1.1 million in 2024, then plummeted by 52.43% to $541962.0 in 2025, then grew by 26.44% to $685235.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Receivables - Net are $685235.0 (Q1 2026), $541962.0 (Q4 2025), and $448990.0 (Q3 2025).